MorphoSys Strengthens Patent Position on MOR202 Program
News Mar 02, 2012
MorphoSys AG has announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the Company's cancer compound MOR202.
The new patent (US 8,088,896) covers MorphoSys's HuCAL antibody against CD38 as well as pharmaceutical compositions comprising the same, and has a scheduled expiry date in 2028, not including any potential regulatory extensions.
"In 2011, MOR202 became our third proprietary antibody program in clinical trials, following MOR103 in rheumatoid arthritis and multiple sclerosis and MOR208 in chronic lymphocytic leukemia," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
Dr. Sproll continued, "Strengthening our intellectual property position on our proprietary products, particularly in our most important markets Europe, the USA and Asia, is of high priority for MorphoSys."
MOR202 is a fully human HuCAL antibody directed against CD38, a therapeutic target for the treatment of multiple myeloma and certain forms of leukemia.
The HuCAL-derived, fully human antibody is currently being tested in a phase 1/2a trial in patients with relapsed/refractory myeloma.
Currently, MorphoSys is prosecuting more than 40 different proprietary patent families world-wide, in addition to those being pursued in cooperation with its partners.
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
XenoGesis and Juniper Pharma Services Strengthen AllianceNews
Campanies extend strategic alliance in early drug development services.READ MORE
Quotient Clinical Signs Cocrystal Agreement with NuformixNews
Partnership to evaluate cocrystal formulations using translational pharmaceutics.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018